公开(公告)号：US20230322941A1

公开(公告)日：2023-10-12

申请号：US18181849

申请日：2023-03-10

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron Yamniuk ,  Mary Struthers ,  Suzanne J. Suchard

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2887 ,  C07K16/28 ,  A61K39/395 ,  C07K2317/92 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/52 ,  C07K2317/30 ,  C07K2317/51 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US10435475B2

公开(公告)日：2019-10-08

申请号：US15118279

申请日：2015-03-09

Applicant: Bristol-Myers Squibb Company

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Xiaoni Liu ,  Wendy L. Trigona ,  Rong Shi ,  Suzanne J. Suchard ,  Karen D. Price ,  Linda M. Gustavson

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/60 ,  A61K39/00

Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.

公开(公告)号：US20180340031A1

公开(公告)日：2018-11-29

申请号：US15988554

申请日：2018-05-24

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron Yamniuk ,  Mary Struthers ,  Suzanne J. Suchard

IPC: C07K16/28 ,  A61K39/395

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US11220550B2

公开(公告)日：2022-01-11

申请号：US15988554

申请日：2018-05-24

Applicant: Bristol-Myers Squibb Company

Inventor： Aaron Yamniuk ,  Mary Struthers ,  Suzanne J. Suchard

IPC: A61K39/395 ,  C07K16/28

Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody and a chimeric antibody with different Fc domains. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.

公开(公告)号：US20200247890A1

公开(公告)日：2020-08-06

申请号：US16842885

申请日：2020-04-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: C07K16/28 ,  A61K47/60 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US20180142023A1

公开(公告)日：2018-05-24

申请号：US15870121

申请日：2018-01-12

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

公开(公告)号：US09908937B2

公开(公告)日：2018-03-06

申请号：US14740709

申请日：2015-06-16

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Murray McKinnon ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Brendan Classon ,  Steve Holmes ,  Olga Ignatovich ,  Christopher Plummer ,  Steve Grant

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/73

Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.

公开(公告)号：US11912769B2

公开(公告)日：2024-02-27

申请号：US17584207

申请日：2022-01-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/60 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US20220144951A1

公开(公告)日：2022-05-12

申请号：US17584207

申请日：2022-01-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: C07K16/28 ,  A61K47/60 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US11180567B2

公开(公告)日：2021-11-23

申请号：US16218077

申请日：2018-12-12

Applicant: Bristol-Myers Squibb Company ,  Domantis Limited

Inventor： Steven G. Nadler ,  James K. Tamura ,  Laura Price ,  Robert P. Rehfuss ,  Suzanne J. Suchard ,  Anish Suri ,  James William Bryson ,  Aaron Yamniuk ,  Steven Grant ,  Olga Ignatovich ,  Philip Drew

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/46 ,  C07K16/18 ,  A61K39/00 ,  A61K38/00

Abstract: Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.